Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BLTE

Belite Bio Inc ADR

Apr 30 • 04:00PM ET

159.16

+4.66 3.02 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: REGN VRTX BIIB GILD MRNA BMY AMGN PFE LLY ABBV

| Held by: SPEM ONEQ APIE GXC BBC EHLS TNXT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.30	Insider Own	0.86%	Shs Outstand	39.97M	Perf Week	-3.22%
Market Cap	6.36B	Forward P/E	164.08	EPS next Y	0.97	Insider Trans	-7.41%	Shs Float	39.62M	Perf Month	-0.18%
Enterprise Value	5.87B	PEG	-	EPS next Q	-0.63	Inst Own	18.17%	Short Float	2.81%	Perf Quarter	-5.83%
Income	-77.61M	P/S	-	EPS this Y	5.78%	Inst Trans	5.73%	Short Ratio	6.57	Perf Half Y	71.10%
Sales	0.00M	P/B	8.13	EPS next Y	144.57%	ROA	-16.64%	Short Interest	1.11M	Perf YTD	-0.50%
Book/sh	19.59	P/C	12.92	EPS next 5Y	-	ROE	-16.94%	52W High	200.00 -20.42%	Perf Year	158.88%
Cash/sh	12.32	P/FCF	-	EPS past 3/5Y	-54.04% -549.64%	ROIC	-10.07%	52W Low	56.10 183.71%	Perf 3Y	450.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.44% 4.38%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-94.37%	Oper. Margin	-	ATR (14)	7.47	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	50.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.61	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	50.02	EPS Q/Q	-117.75%	SMA20	-4.70%	Beta	-1.19	Target Price	211.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-5.36%	Rel Volume	0.34	Prev Close	154.50
Employees	41	LT Debt/Eq	0.00	Earnings	Mar 02 BMO	SMA200	27.64%	Avg Volume	169.59K	Price	159.16
IPO	Apr 29, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	30.44% -	Trades		Volume	58,521	Change	3.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-26	Initiated	BofA Securities	Buy	$195
Jan-06-26	Initiated	Morgan Stanley	Overweight	$191
Dec-02-25	Upgrade	Mizuho	Neutral → Outperform	$194
Nov-24-25	Resumed	Cantor Fitzgerald	Overweight	$154
Nov-20-25	Initiated	Mizuho	Neutral	$105
Dec-14-23	Initiated	Maxim Group	Buy	$60
Jul-28-23	Initiated	Cantor Fitzgerald	Overweight	$43
Jul-26-23	Initiated	SVB Securities	Outperform	$25
Aug-01-22	Initiated	H.C. Wainwright	Buy	$58
Jul-01-22	Initiated	The Benchmark Company	Buy	$57

Apr-27-26 08:00AM	Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit (GlobeNewswire)
Apr-23-26 08:00AM	Belite Bio to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
Apr-21-26 04:00PM	Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
Mar-31-26 08:00AM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire) +6.88%
Mar-04-26 08:43AM	Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald (TipRanks) +5.90%
12:01AM	Loading…
Mar-03-26 12:01AM	Belite Bio Inc (BLTE) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges (GuruFocus.com) -5.46%
Mar-02-26 06:27PM	Belite Bio Q4 Earnings Call Highlights (MarketBeat) -6.68%
08:00AM	Belite Bio to Participate in the Leerink Global Healthcare Conference (GlobeNewswire)
06:00AM	Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-23-26 08:00AM	Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Jan-29-26 08:00AM	Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) (GlobeNewswire)
Jan-27-26 08:00AM	Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1) (GlobeNewswire)
Jan-26-26 09:50AM	Netflix, Meta upgraded: Wall Street's top analyst calls (The Fly)
Dec-02-25 07:22AM	Belite eyes tinlarebant approval after late-stage Stargardt success (Clinical Trials Arena)
Dec-01-25 10:37PM	Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares (GlobeNewswire) +12.06%
06:45PM	Loading…
06:45PM	Why Belite Bio Stock Soared on Monday (Motley Fool)
04:20PM	Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares (GlobeNewswire)
06:00AM	New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease (GlobeNewswire)
03:53AM	Belite continues ascent as Stargardt drug hits mark in late-stage trial (BioPharma Dive)
Nov-20-25 09:40AM	Astera initiated, Nasdaq upgraded: Wall Street's top analyst calls (The Fly) -9.29%
Nov-11-25 12:00AM	Belite Bio Inc (BLTE) Q3 2025 Earnings Call Highlights: Clinical Trials Progress and Financial ... (GuruFocus.com) -9.87%
Nov-10-25 08:00AM	Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-03-25 08:00AM	Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results (GlobeNewswire) +6.13%
Nov-02-25 09:00AM	Belite Bio Announces UK's Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant (GlobeNewswire)
Oct-29-25 08:00AM	Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference (GlobeNewswire) +5.35%
Oct-16-25 08:00AM	Belite Bio to Participate in the 2025 Maxim Growth Summit (GlobeNewswire) +9.61%
Oct-15-25 08:00AM	Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant (GlobeNewswire)
Oct-02-25 08:18AM	3 Lesser-Known Healthcare Names With Major Upside in Store (MarketBeat)
Sep-15-25 05:17AM	Belite Bio wraps up Phase III trial of Stargardt disease treatment (Clinical Trials Arena)
Sep-12-25 08:00AM	Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease (GlobeNewswire)
08:00AM	Loading…
Sep-08-25 08:00AM	Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors (GlobeNewswire)
Aug-27-25 08:00AM	Belite Bio to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 03:07AM	Belite Bio Inc (BLTE) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
Aug-11-25 06:00AM	Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-07-25 08:00AM	Belite Bio Announces Registered Direct Offering of $15 Million (GlobeNewswire)
Aug-06-25 08:00AM	Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-04-25 08:38AM	New Strong Sell Stocks for August 4th (Zacks) +6.19%
08:00AM	Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-23-25 08:00AM	Belite Bio to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-22-25 06:16AM	New Strong Sell Stocks for July 22nd (Zacks)
Jul-03-25 12:01PM	Enrolment concludes in Belite Bios trial of Tinlarebant for geographic atrophy (Clinical Trials Arena)
Jul-02-25 03:00AM	Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy (GlobeNewswire)
May-21-25 03:00AM	Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
May-16-25 08:35AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
May-15-25 07:01PM	Belite Bio Inc (BLTE) Q1 2025 Earnings Call Highlights: Strong Financial Position Amid Rising ... (GuruFocus.com) +8.88%
May-13-25 09:00PM	Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
03:00AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
May-12-25 08:00PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
08:35AM	Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th (GlobeNewswire)
08:00AM	Belite Bio to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
May-08-25 10:44AM	UPDATE - International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
08:35AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
May-07-25 08:00AM	Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 08:00AM	Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 06:00AM	Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
06:00AM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire)
Mar-11-25 03:00AM	Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-04-25 08:00AM	Belite Bio to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-27-25 02:00AM	Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects (GlobeNewswire)
Feb-05-25 10:35PM	Belite Bio Announces Registered Direct Offering of $15 Million (GlobeNewswire)
Nov-27-24 03:00AM	Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 (GlobeNewswire) +5.34%
Nov-12-24 01:00AM	Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-05-24 08:00AM	Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-03-24 04:00PM	Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds (GlobeNewswire)
Oct-14-24 08:00AM	Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Oct-08-24 08:00AM	Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit (GlobeNewswire) +5.93%
Sep-26-24 08:51AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-19-24 02:30AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-17-24 11:22AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-10-24 08:00AM	Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
Sep-03-24 08:00AM	Belite Bio to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Sep-01-24 08:00AM	Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer (GlobeNewswire)
Aug-09-24 09:52PM	BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024 (InvestorPlace)
04:30PM	Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-08-24 08:00AM	Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.33%
Aug-05-24 07:10PM	Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-08-24 08:00AM	Belite Bio to Present at the JonesHealthcare Seaside Summit (GlobeNewswire) +6.81%
Jun-12-24 02:55AM	Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan (GlobeNewswire)
May-14-24 08:00AM	Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference (GlobeNewswire)
07:53AM	BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024 (InvestorPlace)
05:17AM	Belite Bio's Q1 Loss Narrows (MT Newswires)
May-13-24 09:50PM	Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-08-24 08:00AM	Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 08:15AM	Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant (GlobeNewswire)
08:00AM	Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting (GlobeNewswire)
May-01-24 04:15PM	Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Apr-26-24 06:21AM	Belite Bio Unveils Plan to Offer 651,380 American Depository Shares (MT Newswires)
Apr-25-24 07:15PM	Belite Bio Announces $25 Million Registered Direct Offering (GlobeNewswire)
Apr-10-24 09:55AM	Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect? (Zacks)
Mar-22-24 08:00AM	Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan (GlobeNewswire)
Mar-11-24 10:28PM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire) -12.47%
09:27PM	Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 08:00AM	Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-04-24 08:00AM	Belite Bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-07-24 08:00AM	Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-30-23 08:00AM	Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference (GlobeNewswire) +10.10%
Nov-20-23 08:00AM	Belite Bio to Participate in the BTIG Ophthalmology Day (GlobeNewswire)
Nov-13-23 08:15PM	Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Nov-10-23 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)

Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MATA NATHAN L.	Chief Scientific Officer	Apr 29 '26	Sale	155.82	1,000	155,817	5,666	Apr 30 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 28 '26	Sale	159.16	1,000	159,162	6,666	Apr 29 04:32 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 27 '26	Sale	162.64	1,000	162,641	7,666	Apr 28 04:28 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 24 '26	Sale	159.56	1,000	159,556	8,666	Apr 27 04:52 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 23 '26	Sale	166.28	1,000	166,284	9,666	Apr 24 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 22 '26	Sale	170.38	1,000	170,384	10,666	Apr 23 04:19 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 21 '26	Sale	166.00	1,000	166,000	11,666	Apr 22 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 20 '26	Sale	163.59	1,000	163,595	12,666	Apr 21 05:28 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 17 '26	Sale	161.63	1,000	161,630	13,666	Apr 20 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 16 '26	Sale	160.38	1,000	160,381	14,666	Apr 20 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 15 '26	Sale	168.30	1,000	168,298	15,666	Apr 16 04:15 PM
Nathan L. Mata	Officer	Apr 15 '26	Proposed Sale	171.93	16,666	2,865,385		Apr 15 05:23 PM
Lin Yu-Hsin	Chief Executive Officer	Apr 09 '26	Sale	181.45	9,200	1,669,339	170,934	Apr 13 04:15 PM
Chen Wan-Shan	Director	Apr 09 '26	Sale	180.43	1,100	198,473	9,096	Apr 13 04:15 PM
Chuang Hao-Yuan	Chief Financial Officer	Apr 09 '26	Sale	181.50	6,200	1,125,303	93,800	Apr 13 04:15 PM
Yu-Hsin Lin	CEO, Chairman	Apr 09 '26	Proposed Sale	178.73	136,000	24,307,280		Apr 09 04:52 PM
Hao-Yuan Chuang	Officer, Director	Apr 09 '26	Proposed Sale	178.73	100,000	17,873,000		Apr 09 04:43 PM
Wan Shan Chen	affiliate	Apr 09 '26	Proposed Sale	217.76	10,196	2,220,250		Apr 09 12:17 PM
Wan Shan Chen	Affiliate	Oct 17 '25	Proposed Sale	121.94	9,550	1,164,500		Oct 17 09:29 AM
Wan Shan Chen	affiliate	Oct 16 '25	Proposed Sale	85.00	1,050	89,250		Oct 16 12:26 PM
Hao-Yuan Chuang	Officer, Director	Oct 13 '25	Proposed Sale	79.77	70,054	5,588,208		Oct 14 03:05 PM
Wan Shan Chen	affiliate	Oct 13 '25	Proposed Sale	80.00	1,050	84,000		Oct 14 12:44 PM
Yu-Hsin Lin	CEO, Chairman	Sep 18 '25	Proposed Sale	73.00	96,950	7,077,350		Sep 18 04:38 PM
Nathan L. Mata	Officer	Aug 21 '25	Proposed Sale	63.42	30,000	1,902,600		Aug 21 05:17 PM
Yu-Hsin Lin	CEO, Chairman	May 21 '25	Proposed Sale	64.81	120,400	7,803,124		May 21 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLTE

Belite Bio Inc ADR

Upgrade your Finviz experience